head activator peptide has been researched along with Parkinson Disease in 1 studies
*Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Franke, I; Gelderblom, M; Glassmeier, G; Ignatov, A; Imai, Y; Rezgaoui, M; Schaller, HC; Süsens, U; Takahashi, R; Urny, J | 1 |
1 other study(ies) available for head activator peptide and Parkinson Disease
| Article | Year |
|---|---|
The neuropeptide head activator is a high-affinity ligand for the orphan G-protein-coupled receptor GPR37.
Topics: Animals; Calcium; Calcium Signaling; Calcium-Calmodulin-Dependent Protein Kinases; Cell Death; Chlorocebus aethiops; COS Cells; Humans; Mitogens; Neuropeptides; Oocytes; Parkinson Disease; Phosphatidylinositol 3-Kinases; Pyrrolidonecarboxylic Acid; Receptors, G-Protein-Coupled; Transfection; Xenopus laevis | 2006 |